Rodolfo Murillas

Madrid, MD 28040, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa.

Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa.

Journal: Human gene therapy

Published: May 28, 2025

Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.

Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 03, 2024

Hedgehog Signalling Modulates Immune Response and Protects against Experimental Autoimmune Encephalomyelitis.

Hedgehog Signalling Modulates Immune Response and Protects against Experimental Autoimmune Encephalomyelitis.

Journal: International journal of molecular sciences

Published: February 19, 2022

Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors.

Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors.

Journal: Molecular therapy. Methods & clinical development

Published: January 13, 2022

Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system.

Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system.

Journal: Gene therapy

Published: August 19, 2020

Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.

Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 08, 2020

Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome.

Efficient CRISPR-Cas9-Mediated Gene Ablation in Human Keratinocytes to Recapitulate Genodermatoses: Modeling of Netherton Syndrome.

Journal: Molecular therapy. Methods & clinical development

Published: February 07, 2020

Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.

Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: October 01, 2018

Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.

Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells.

Journal: Molecular therapy. Nucleic acids

Published: December 22, 2017

An RNA-targeted therapy for dystrophic epidermolysis bullosa.

An RNA-targeted therapy for dystrophic epidermolysis bullosa.

Journal: Nucleic acids research

Published: May 11, 2017

Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Journal: Molecular therapy. Nucleic acids

Published: February 04, 2016

Identification of two rare and novel large deletions in ITGB4 gene causing epidermolysis bullosa with pyloric atresia.

Identification of two rare and novel large deletions in ITGB4 gene causing epidermolysis bullosa with pyloric atresia.

Journal: Experimental dermatology

Published: December 19, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026